
SCHEMA



Footnote[a] HER-2 targeted therapy continuation/discontinuation at the discretion of treating physician.

Footnote[b] For patients on Arm 1, carvedilol is reimbursed by the study while the patient is on study for up to 108 weeks from randomization. Upon removal from study, non-reimbursed carvedilol continuation is at the discretion of the treating physician.

Footnote[c] Patients already on beta blocker, ARB or ACE inhibitors.

SWOG Authorized Document